玻璃体内注射雷珠单抗治疗新生血管性年龄相关性黄斑变性后房水闪光水平的评估
Evaluation of Aqueous Flare Levels Following Intravitreal Ranibizumab Injection for Neovascular Age-related Macular Degeneration.
作者信息
Uzun Aslihan, Yalcindag Fatime Nilufer, Demirel Sibel, Batýoðlu Figen, Ozmert Emin
机构信息
a Ordu University , Training and Research Hospital, Department of Ophthalmology , Ordu , Turkey.
b Ankara University, Faculty of Medicine , Department of Ophthalmology , Ankara , Turkey.
出版信息
Ocul Immunol Inflamm. 2017 Apr;25(2):229-232. doi: 10.3109/09273948.2015.1108445. Epub 2016 Jan 30.
PURPOSE
To evaluate aqueous flare levels following intravitreal ranibizumab injection for neovascular age-related macular degeneration (AMD).
METHODS
In total, 81 eyes of 79 patients who underwent intravitreal ranibizumab injection for neovascular AMD were included. Aqueous flare was evaluated before pupillary dilatation with Kowa FM-600 laser flare meter at baseline, and 1 day, and 1 month after intravitreal administration of ranibizumab 0.5 mg (0.05 mL).
RESULTS
The mean anterior chamber flare was 10.7 ± 6.8 (range: 1.5-35.4) ph/ms before the injection, 12.5 ± 8.9 (range: 0.3-43) ph/ms on the first day, and 9.9 ± 5.7 (range: 0.2-28.4) ph/ms in the first month. On the first day, a subtle increasing of flare was observed. However, the difference between the mean aqueous flare levels at baseline and postoperative first day and first month was not statistically different (p>0.05).
CONCLUSIONS
No significant short-term intraocular inflammation was noted in these eyes receiving ranibizumab for the treatment of neovascular AMD.
目的
评估玻璃体内注射雷珠单抗治疗新生血管性年龄相关性黄斑变性（AMD）后的房水闪光水平。
方法
总共纳入了79例接受玻璃体内注射雷珠单抗治疗新生血管性AMD的患者的81只眼。在基线、玻璃体内注射0.5mg（0.05mL）雷珠单抗后的1天和1个月，使用Kowa FM-600激光闪光仪在瞳孔散大前评估房水闪光。
结果
注射前平均前房闪光为10.7±6.8（范围：1.5 - 35.4）ph/ms，第一天为12.5±8.9（范围：0.3 - 43）ph/ms，第一个月为9.9±5.7（范围：0.2 - 28.4）ph/ms。在第一天，观察到闪光有轻微增加。然而，基线、术后第一天和第一个月的平均房水闪光水平之间的差异无统计学意义（p>0.05）。
结论
在这些接受雷珠单抗治疗新生血管性AMD的眼中，未观察到明显的短期眼内炎症。
Zotero 插件